BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Robert W. Baird from $117.00 to $73 ...
Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.
Hosted on MSN25d
PRAX stock soars to 52-week high, hits $90.33 amid robust gainsP raxis Precision Medicines Inc. stock has reached a new 52-week high, with shares climbing to $90.33. According to InvestingPro data, the company's market capitalization now stands at $1.7 ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $132.2, a high estimate of ...
Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing ...
Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Praxis Precision Medicines ...
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
2 market experts have recently issued ratings for this stock, with a consensus target price of $130.5.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback